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Open access under the ElIn the last decades, a series of compounds, including quinones and polyphenols, has been described as
having anti-ﬁbrillogenic action on a-synuclein (a-syn) whose aggregation is associated to the pathogen-
esis of Parkinson’s disease (PD). Most of these molecules act as promiscuous anti-amyloidogenic agents,
interacting with the diverse amyloidogenic proteins (mostly unfolded) through non-speciﬁc hydrophobic
interactions. Herein we investigated the effect of the vitamins K (phylloquinone, menaquinone and men-
adione), which are 1,4-naphthoquinone (1,4-NQ) derivatives, on a-syn aggregation, comparing them
with other anti-ﬁbrillogenic molecules such as quinones, polyphenols and lipophilic vitamins. Vitamins
K delayed a-syn ﬁbrillization in substoichiometric concentrations, leading to the formation of short,
sheared ﬁbrils and amorphous aggregates, which are less prone to produce leakage of synthetic vesicles.
In seeding conditions, menadione and 1,4-NQ signiﬁcantly inhibited ﬁbrils elongation, which could be
explained by their ability to destabilize preformed ﬁbrils of a-syn. Bidimensional NMR experiments indi-
cate that a speciﬁc site at the N-terminal a-syn (Gly31/Lys32) is involved in the interaction with vitamins
K, which is corroborated by previous studies suggesting that Lys is a key residue in the interaction with
quinones. Together, our data suggest that 1,4-NQ, recently showed up by our group as a potential scaffold
for designing new monoamine oxidase inhibitors, is also capable to modulate a-syn ﬁbrillization in vitro.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Parkinson’s disease (PD) is the second most common age-
related neurodegenerative disease and is characterized by the loss
of dopaminergic neurons in the substantia nigra pars compacta
and dopamine deﬁciency in the striatum (Hoehn and Yahr, 1967;
Lees et al., 2009; Hughes et al., 1992; Burns et al., 1983). Although
the etiology of PD is unknown, the neurodegeneration has been
suggested to be result of a combination of factors including dam-
ages associated with oxidative stress (Jenner, 2003) and the forma-
tion of cytotoxic inclusion composed by the protein a-synuclein
(a-syn) (Polymeropoulos et al., 1997).
Physiologically, a-syn is believed to exist as a disordered mono-
mer (Fauvet et al., 2012), which aggregates into ﬁbrillar structures
that can accumulate as intracellular inclusions and abnormal neu-
ritis (Lewy bodies and Lewy neuritis). However, some studies indi-
cate that a-syn might behave as a helicoidal tetramer that likelyx: +55 21 2562 7265.
sevier OA license.undergoes destabilization before protein aggregates into ﬁbrillar
assemblies (Bartels et al., 2011). Besides PD, a-syn is involved in
some variants of Alzheimer’s disease (AD), dementia with lewy
bodies and multiple system atrophy (Goedert, 2001; Spillantini
et al., 1997; Baba et al., 1998; Wakabayashi et al., 1998). In vitro
studies show that a-syn mutation A30P, linked to early onset cases
of PD (Conway et al., 2000), increases the formation of nonﬁbrillar
oligomers (protoﬁbrils). Interestingly, a-syn protoﬁbrils but not
either ﬁbrils or the monomer, cause permeabilization of synthetic
vesicles similarly to found with some pore-forming protein toxins
(Volles et al., 2001; Lashuel et al., 2002).
In vitro assays have demonstrated that several compounds,
including catecholamines, anti-parkinsonian drugs and certain
natural products inhibit the ﬁbrillization of a-syn, leading to the
formation of non-toxic aggregates (Ono and Yamada, 2006; Ono
et al., 2007; Follmer et al., 2007; Braga et al., 2011). However, many
of these molecules, notably those highly hydrophobic, behave as
promiscuous anti-ﬁbrillogenic agents interacting with both a-syn
and amyloid-b peptide (involved in AD) by non-speciﬁc hydropho-
bic interactions. In light of these ﬁndings we are looking for
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monomer leading to the formation of aggregates incapable to pro-
mote vesicle permeabilization.
The 1,4-naphthoquinones (1,4-NQ) have been described to ex-
hibit a broad spectrum of activities on important targets associ-
ated to neurodegenerative disorders including inhibition of the
aggregation of amyloid-b peptide (Bermejo-Bescós et al., 2010),
inhibition of Hsp90 (Hadden et al., 2009) and inhibition of
monoamine oxidase (MAO) activity (Coelho-Cerqueira et al.,
2011). For instance, the 2,3,6-trimethyl-1,4-naphthoquinone, a
component of ﬂue-cured tobacco leaves and smoke, is a compet-
itive inhibitor of both MAO-A and MAO-B that exhibits protective
properties against MPTP toxicity in mice (Castagnoli et al., 2003).
The 1,4-NQ scaffold is usually found in bioactive molecules such
as vitamins K, which are characterized by a methylated naphtho-
quinone ring with an aliphatic chain substituent at the 3-position.
Interestingly, menadione (2-methyl-1,4-naphthoquinone; vitamin
K3), which acts as a precursor of vitamin K2, has been recently
pointed out as a competitive and reversible inhibitor of human
MAO as selective for MAO-B as rasagiline (Coelho-Cerqueira
et al., 2011). Inhibition of monoamine oxidase activity is one
of the most important pharmacological targets in the therapy
for PD.
Herein, we investigated the effects of multiple forms of vitamin
K [phylloquinone (K1), menaquinone (MK-4) (K2) and menadione
(K3)] and 1,4-NQ itself on a-syn ﬁbrillization. Our results suggest
that these molecules prevent a-syn ﬁbrillization by interacting
with speciﬁc residues of a-syn monomer located at N-terminal re-
peat domain (Gly31/Lys32) as indicated by 1H-15N HSQC NMR
data. This interaction results in protein assemblies (amorphous
aggregates and small ﬁbrils) with a reduced capacity to produce
vesicle leakage compared with the control. Taken together, our
data suggest that 1,4-NQ, recently reported by for our group as a
potential scaffold for designing new MAO inhibitors, is also an
important scaffold to develop drugs targeting a-syn ﬁbrillization.2. Methods
2.1. Expression and puriﬁcation of a-syn
The pT7-7-wt plasmid (kindly provided by H.A. Lashuel and D.
Foguel) containing wild-type (WT) human a-syn was transfected
into BL21(DE3)pLysS E. coli and the expression induced by the
addition of isopropyl b-D-thiogalactopyranoside (IPTG). The
expression and puriﬁcation procedures were carried out as de-
scribed by Conway et al. (1998) with modiﬁcations. Brieﬂy, the
expression was induced at absorbance (600 nm) 0.5 with 0.5 mM
IPTG for 4 h and then cells were harvested by centrifugation
(8000g) for 30 min. The pellet was ressuspended in 20 mM Tris–
HCl, 5 mM EDTA, 1 mM PMSF pH 8.0 and then cells were disrupted
by sonication. The supernatant was dialyzed overnight against
20 mM Tris–HCl, pH 8.0, 1 mM EDTA and then loaded onto a
Q-Sepharose Fast Flow column (GE Biosciences). The fraction
eluted with 0.2–0.4 M NaCl was loaded onto a Sephacryl S-200
(GE Biosciences) equilibrated with 20 mM Tris–HCl, pH 7.5,
150 mM NaCl and the fractions containing a-syn were combined
and dialyzed against MilliQ water and further lyophilized. Puriﬁed
a-syn showed a single 18 kDa band in 15% SDS–PAGE.2.2. Measurement of a-syn ﬁbrillization and ﬁbril-destabilizing
activity
Puriﬁed a-syn (100 lM) in 20 mM Tris, pH 7.4, 0.02% sodium
azide, 150 mM NaCl plus 5 lM Thioﬂavin-T (Thio-T) was incubated
in the presence of 5 to 100 lM of 1,4-NQ, menadione, menaquin-one or phylloquinone. DMSO was used as control since all com-
pounds was dissolved in this solvent. The ﬁbrillization was
monitored in situ in a 96-well plate (Greiner 96-well white plate)
at 37 C in Eppendorf Thermomixer with continuous shaking
(350 rpm). Thio-T binding was evaluated by ﬂuorescence intensity
by exciting at 446 nm and collecting the emission at 485 nm (slits:
5 nm) in a Cary Eclypse Fluorimeter (Agilent Inc.). The effective
concentrations (EC50) were deﬁned as the concentration of drug
that inhibits the formation of a-syn ﬁbrils to 50% of the control va-
lue (a-syn plus DMSO). Fibril destabilization activity was mea-
sured by incubating 20 lM mature a-syn ﬁbrils (in terms of
monomer concentration) in 20 mM Tris, pH 7.4, 0.02% azide,
150 mM NaCl and 5 lM Thio-T in a 96-well plate at 37 C under
agitation (350 rpm) in the presence of 5–100 lM 1,4-NQ, menadi-
one, menaquinone or phylloquinone. Fibril disassembling was
monitored by Thio-T ﬂuorescence as described above.
2.3. Nucleation-dependent ﬁbrillization of a-syn
Seeds of a-syn were prepared by incubation of 100 lM a-syn in
20 mM Tris, pH 7.4, 0.02% azide, 150 mM NaCl for 8–10 days at
37 C under agitation (350 rpm) followed by sonication by ultra-
sound for 60 min. For the ﬁbrillization in seeding conditions,
a-syn monomer (40 lm) in PBS buffer plus 5 lM Thio-T were
incubated in presence of seeds (5%, w/w) at 37 C, without shaking.
To evaluate the effect of vitamins K and 1,4-NQ, a-syn was
preincubated for 30 min with equimolar concentration of these
compounds prior the addition of seeds. Equivalent amounts of
DMSO were used as control.
2.4. Atomic force microscopy (AFM)
An aliquot of 5 ll, withdrawn of the a-syn solutions (100 lM
monomer) under different aggregation conditions, was deposited
on freshly cleaved mica. After 5 min incubation at room tempera-
ture, it was rinsed with MilliQ water, gently dried under nitrogen
ﬂow and used for AFM imaging, as described below. The acquisi-
tion of AFM images was done by using a Nanowizard JPK AFM
(Berlin, Germany), operating in dynamic mode under ambient
conditions, with 46% relative humidity, using AC240 cantilevers
(Veeco, USA) with a spring constant of 2 N/m and a resonance
frequency of 70 kHz. The nominal tip radius was <10.0 nm.
AFM image analysis was performed using the JPK Image Processing
software.
2.5. NMR experiments
The NMR measurements were carried out at 12 C on a Bruker
Avance III (Bruker Biospin GmbH, Reinstetten, Germany) operat-
ing at 1H frequency of 800 MHz. The sample contained 100 lM
15N-a-syn in PBS pH 7.0 [10% D2O (v/v)] in the presence or
absence of equimolar concentration of phylloquinone, menaquin-
one, menadione or 1,4-NQ. Equivalent amounts of DMSO were
used as control. The 1H-15N Heteronuclear Single Quantum
Coherence (HSQC) experiments were done with WATERGATE
water suppression (Piotto et al., 1992). The data were processed
with TOPSPIN 3.1 (Bruker Biospin Corporation, USA) and the
assignment was introduced using CCPNmr Analysis (Vranken
et al., 2005). The 1H-15H HSQC spectra of a-syn in the absence
or in the presence of some compounds were assigned according
to Rao et al. (2009).
2.6. Vesicle leakage experiments
Large unilamellar vesicles (LUVs) were prepared by the extru-
sion method (Hope et al., 1985). All preparations were made in
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by carrying out the experiments in presence of 100 mM NaCl. A
two-syringe extruder was used, equipped with a polycarbonate ﬁl-
ter (Nuclepore, Whatman) with 80-mm pore size. Twenty pas-
sages were performed each time. L-a-phosphatidyl-DL-glycerol
(PG) (Avant Polar Lipids, USA) (10 mg) were solubilized in 500 lL
of chloroform and the solvent completely evaporated in a nitrogen
atmosphere until the formation of a uniform lipid ﬁlm on the inner
surface of the glass tube. A self-quenching solution of 100 mM car-
boxyﬂuorescein [20,70-bis-(2-carboxyethyl)-5-(and-6)-carboxy-
ﬂuorescein; Molecular Probes], in 25 mM Tris pH 7.5, was
entrapped in the LUVs by mixing 500 lL of carboxyﬂuorescein
solution with the lipid ﬁlm previously prepared. The free labels
were separated from the labeled vesicles by gel ﬁltration in Seph-
acryl S-100 column (GE Bioscience). The leakage promoted by a-
syn aggregates (ﬁnal concentration of 10 lM in 25 mM Tris, pH 7.4,
100 mM NaCl), generated after 3 days of incubation at 37 C under
agitation, was evaluated by the carboxyﬂuorescein release assay
(Kendall and MacDonald, 1982). The concentration of LUVs in the
experiment was estimated based on the absorbance of the ﬂuores-
cent probe (490 nm). In all experiments we have considered a ﬁnal
concentration of LUV corresponding to value of absorbance of 0.1
at 490 nm. In the leakage assays, ﬂuorescence intensity (excitation
at 490 nm and emission 518 nm) of the reactional mixture was re-
corded as a function of time. All measurements were carried out in
a Cary Eclipse ﬂuorescence spectrophotometer (Agilent Inc). The
absence of leakage (0%) corresponds to the ﬂuorescence of the ves-
icles at time zero; 100% leakage was taken as the value of ﬂuores-
cence intensity obtained after addition of 1% (v/v) Triton X-100.
The degree of permeabilization was then inferred from the rela-
tion: % leakage = [(F  F0)/(Ft  F0)]  100, where F is the ﬂuores-
cence intensity after the addition of a-syn aggregates; F0 is the
initial ﬂuorescence of the intact LUV suspension and Ft is the ﬂuo-
rescence after the addition of Triton X-100.3. Results and discussion
3.1. Vitamin K inhibit a-syn ﬁbrillization
Recently, the 1,4-NQ scaffold has been reported to exhibit
important activities on biochemical pathways associated to neuro-
degenerative disorders such as inhibition of Hsp90, inhibition of b-
secretase (involved in amyloid-b proteolysis), inhibition of MAO-A
and MAO-B isoforms (involves in both PD and AD) and inhibition of
amyloid-b ﬁbrillization (Hadden et al., 2009; Bermejo-Bescós et al.,
2010; Coelho-Cerqueira et al., 2011).
Herein, the in vitro aggregation properties of a-syn were inves-
tigated in the presence of vitamins K by monitoring the formation
of ﬁbrillar structure through the Thio-T ﬂuorescence as well as by
AFM imaging. The chemical structures of these molecules and
other anti-ﬁbrillogenic compounds discussed in this article are
shown in the Fig. 1. The compounds were assayed in a micromolar
range to keep the molar ratio protein/compound at 1:2 to 10:1,
although physiologically vitamins K levels do not reach micromo-
lar concentrations. We have also evaluated the effect of 1,4-NQ
since all members of vitamins K displays this scaffold. Fig. 2 shows
the characteristic sigmoidal curves for the ﬁbrillization of a-syn at
37 C and under agitation (350 rpm), given by the ﬂuorescence of
Thio-T in a speciﬁc time (F) divided by the initial value (F0). Since
the compounds tested were solubilized in 100% DMSO, equivalent
amounts of the solvent were used as control [1–5% (v/v)]. All mem-
bers of vitamin K as well as 1,4-NQ produced a dose-dependent
decreasing of a-syn ﬁbrillization (Fig. 2A–D), whereas no effect
was observed for DMSO alone. In the kinetic of ﬁbrillization, these
compounds produced a slight prolongation of lag phase accompa-nied by a reduction of the content of ﬁbrils formed at the steady
state. This effect is distinct from other compounds such as selegi-
line, an anti-parkinsonian drug, which delays the nucleation step
in the aggregation process but it does not change the ﬁnal content
of ﬁbrils (Braga et al., 2011). The EC50 values were estimated by
plotting the percentage of ﬂuorescence at the steady state, ob-
tained from the sigmoidal curve ﬁtting of the data presented in
Fig. 2, versus the logarithm of inhibitor concentration in micromo-
lar (Fig. 2A–D, insets). For all compounds assayed, the inhibition
was veriﬁed at substoichiometric concentrations. All molecules
display similar ability to inhibit a-syn ﬁbrillization with EC50 val-
ues in range of 15–30 lM. Interestingly, menadione (EC50 value
of 18 lM for a-syn ﬁbrillization) did not exhibit inhibitory activity
on amyloid-b peptide (Bermejo-Bescós et al., 2010).
The EC50 values determined by using Thio-T as a ﬁbril-probe
must be carefully evaluated, presumably because Thio-T assay
might be biased by the presence of certain exogenous compounds,
notably polyphenols, resulting in a reduction of EC50 values and
overestimation of the anti-ﬁbrillogenic activities. Polyphenols are
usually chromophoric and even intrinsically ﬂuorescent since their
phenolic aromatic rings are often connected by conjugated sys-
tems, resulting in strong p? p⁄ electronic transitions. For in-
stance, by using real-time Thio-T assay, quercetin and curcumin
(referred as potent anti-ﬁbrillogenic molecules) cause signiﬁcant
inner ﬁlter effects leading to effective quenching of the Thio-T ﬂuo-
rescence (Hudson et al., 2009). Herein, we evaluated the effect of
vitamins K in both in situ real-time Thio-T assays and by single
time-point dilution Thio-T-type assay and no signiﬁcant differ-
ences were observed. Additionally, vitamins K did not display
any effect on Thio-T ﬂuorescence emission spectra over short per-
iod of time when these compounds were added to samples con-
taining ﬁbrils plus Thio-T (data not shown).
Fig. 2E shows the AFM images of a-syn aggregates at end of the
aggregation process in the presence of vitamins K or DMSO
(control). We can note the presence of large ﬁbrillar structures
(radius: 101 ± 49 nm and height: 8.9 ± 6.1 nm) in the sample
containing 1% (v/v) DMSO instead of the compounds tested. Similar
morphology was veriﬁed for a-syn incubated in the presence of
buffer (data not shown). On the other hand, a-syn incubated
with phylloquinone or menaquinone at a molar ratio of 2:1
protein/compound displays amorphous aggregates besides short
ﬁbrillar structures. a-syn ﬁbrils exhibited average radii of
57 ± 26 nm (height of 5.7 ± 1.5 nm) and 46 ± 18 nm (height of
4.6 ± 1.2 nm) when incubated in the presence of phylloquinone
and menaquinone, respectively. The radius of these ﬁbrils was
statistically smaller than those observed for ﬁbrils in the presence
of buffer or DMSO (p values for DMSO versus phylloquinone and
menaquinone were <0.05 and <0.01, respectively). Similar results
were observed for menadione. For 1,4-NQ, only few small ﬁbrils
were noted besides amorphous aggregates. It is important to note
that in all cases, ﬁbrils coexist with amorphous aggregates.
Importantly, in the presence of the vitamins K, we did not observe
a signiﬁcant population of oligomers at the steady state, at least by
using AFM. Note that a-synuclein oligomers (2–7 nm), including
those acting as pore-forming toxins (Volles et al., 2001; Lashuel
et al., 2002), are easily observed by AFM (Apetri et al., 2006).
Several anti-ﬁbrillogenic molecules inhibit the ﬁbrillation process
resulting in the formation oligomeric species that, as transient
intermediates of the aggregation process, display diverse morphol-
ogies and biological properties (Caughey and Lansbury, 2003).
Besides vitamins K, multiforms of vitamin A have been reported
as inhibitors of a-syn ﬁbrillization (Ono and Yamada, 2007). Unfor-
tunately, biological properties of a-syn species formed in the pres-
ence of retinols have not been evaluated. The low EC50 values
showed by retinol, retinal and retinoic acid (0.19–3 lM) might be
associated to the high hydrophobic character of these molecules.
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Fig. 1. Chemical structures of the anti-ﬁbrillogenic molecules: vitamins K, vitamin A, CoQ10, baicalein, PQQ, dopaminechrome and selegiline.
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also nonpolar molecules, they contain the reactive quinone group,
which is capable to react with amines to form a Schiff base. On the
other hand, retinol derivatives are largely hydrophobic and contain
a single polar group [carboxylic acid (retinoic acid), hydroxyl
(retinol) or aldehyde group (retinal)] on the extremity of a long
aliphatic chain (Fig. 1). Therefore, the anti-ﬁbrillogenic activity of
vitamins A is presumably associated to their ability to interact
with the highly hydrophobic NAC domain of a-syn rather than
any speciﬁc site. Furthermore, these molecules efﬁciently inhibit
the aggregation of both a-syn and amyloid-b peptide (Ono and
Yamada, 2007) that are unfolded proteins without any sequence
similarity and with a large amount of hydrophobic residues
exposed to water. Therefore, we can speculate that retinol deriva-
tives behave as promiscuous anti-ﬁbrillogenic agents. In case of
phylloquinone and menaquinone, the long aliphatic substituent
in the 3-position of 1,4-NQ ring does not improve their ability to
inhibit a-syn aggregation as was expected for a hydrophobic
interaction. Conversely, phylloquinone and menaquinone have
higher EC50 values than either menaquinone or and 1,4-NQ
(29–30 lM against 18–15 lM). Interestingly, ubiquinol (CoQ10),
with a 1,4-benzoquinone scaffold and a long aliphatic substituent
at the position 3 in the ring, has similar structure to vitamins K
(Fig. 1) and displays a EC50 value of 10 lM, which is in the same
range of vitamins K (Ono and Yamada, 2007).
3.2. Vitamins K affect the nucleation step of a-syn ﬁbrillization
a-syn ﬁbrillization is a nucleation-dependent process involving
two main pathways: a nucleation step (lag phase), which results in
protoﬁbrils formation, followed by elongation step (exponential
phase) in which the ﬁbrils grow. Anti-ﬁbrillogenic compounds
might interfere in one of these steps or in both and thus generate
in a wide spectrum of species (small oligomers, protoﬁbrils, ﬁbrils
or amorphous aggregates).To verify if the observed effect of vitamins K is restricted to the
nucleation step, a-syn was incubated under aggregating conditions
and then 50 lM of vitamins K or 1,4-NQ (or 2% DMSO) were added
to the samples when the lag phase was already concluded. Fig. 3A
shows the Thio-T ﬂuorescence at the steady state in the system in
which the compounds were added to a-syn monomer at either the
initial time or after 3 days under aggregation conditions. We can
observe that the effect of phylloquinone and menaquinone was
prevented when lag phase was completed, suggesting that these
compounds might be interfering in the formation of the nucleus.
For menadione and 1,4-NQ, the inhibitory effect remained even
these compounds were added after the lag phase, which can be as-
cribed to either a destabilization of preexisting nucleus/protoﬁbrils
or an inhibition of the ﬁbril elongation process. To investigate
these two hypotheses, a-syn aggregation was carried out in seed-
ing conditions.
It has been established that preformed ﬁbrils submitted to son-
ication by ultrasound act as ‘‘seeds’’ when they are added to a-syn
monomer, resulting in acceleration of the ﬁbrillization process by
shortening the nucleation phase. These seeds are fragments of ﬁ-
brils acting as a template for addition of a-syn monomer to ﬁbril
but they are structurally different than the nucleus specie. Fig. 3B
shows that the addition of seeds to a-syn monomer signiﬁcantly
abolished the lag phase and accelerated the formation of ﬁbrils.
In the absence of agitation, no aggregation was observed in unsee-
ding condition (open symbols). When a-syn monomer plus seeds
is incubated in the presence of equimolar concentration of phyllo-
quinone or menaquinone, the inhibitory effect of these compounds
was abolished, suggesting these compounds did not interfere in the
ﬁbril elongation process. On the other hand, seeds did not abolish
the effect of menadione or 1,4-NQ on the ﬁbrillization process.
The inhibitory effect of menadione and 1,4-NQ on a-syn ﬁbril-
lization in the presence of seeds could be ascribed to either an inhi-
bition of the ﬁbril elongation process or a destabilization of
preexisting seeds. If the seeds have their structure destabilized
A B
C D
E
Fig. 2. Effect of vitamins K and 1,4-NQ on a-syn ﬁbrillization. Kinetic of ﬁbrillization of 100 lM de human WT-a-syn incubated at 37 C (350 rmp) in the presence of several
concentrations of vitamins K: phylloquinone (A), menaquinone (B), menadione (C) or 1,4-NQ (D). The content of ﬁbrils was monitored in situ by measurement of Thio-T
ﬂuorescence. The insets show the determination of EC50 by plotting of the percentage of ﬂuorescence at the steady state obtained from the sigmoidal curve ﬁtting versus the
logarithm of inhibitor concentration in lM. (E) AFM images of a-syn aggregates generated when 100 lM de a-syn monomer was incubated at 37 C (350 rmp) with 50 lM of
phylloquinone, menaquinone, menadione or 1,4-NQ for ten days. Bars: 500 nm. Fibrillar structures were highlighted. DMSO was used as control.
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for ﬁbrils growth. Thus the effect of 1,4-NQ and vitamins K on the
disaggregation of preformed ﬁbrils of a-syn was investigated. As
shown in Fig. 3C, the Thio-T ﬂuorescence remains unaltered during
the incubation of a-syn ﬁbrils at 37 C under agitation, in the pres-
ence of 1% DMSO. No differences were observed between DMSO
and buffer (data not shown). However, the Thio-T ﬂuorescence
dose-dependently decrease immediately after the addition of 1,4-
NQ (Fig. 3C). AFM images (insets) show that only amorphous
aggregates were observed after 7 days of incubation in the pres-
ence of 50 lM 1,4-NQ. Although in lower extension than 1,4-NQ,
menadione is also capable to destabilize preformed ﬁbrils of a-
syn (Fig. 3D). In this case, the concomitant presence of ﬁbrils and
amorphous aggregates were observed by AFM after 7 days of incu-
bation. Phyloquinone and menaquinone did not display any effect
on the stability of ﬁbrils (data not shown), which could be associ-
ated to their higher molecular volumes in comparison with mena-
dione or 1,4-NQ, that reduce their diffusion into ﬁbril structure and
hence their interaction with protein sites involved in the ﬁbrildestabilization process. These data suggest that the ability to disso-
ciate preformed ﬁbrils exhibited by vitamins K was not necessarily
associated with their capacity to inhibit a-syn ﬁbrillization.
Certain anti-parkinsonian drugs are capable to inhibit or retard
a-syn aggregation (Ono et al., 2007). One of these compounds is
selegiline, which binds to a-syn and delay the formation of
protein ﬁbrils (Braga et al., 2011). Selegiline inhibits a-syn
ﬁbrillation precisely by delaying the nucleation step but not
interfering in the elongation process, similarly to vitamins K.
However, selegiline was effective only in large micromolar
concentrations whereas vitamins K exhibit inhibitory activity
at substoichiometric concentrations. Selegiline, with a tertiary
amine and an acetylene group, is not structurally related with
vitamins K or other anti-amyloidogenic molecules (Fig. 1).
3.3. Effect of vitamins K on vesicle leakage induced by a-syn
In the early stage of ﬁbrillization process, the system is
populated by soluble oligomers and protoﬁbrils with diverse
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Fig. 3. Vitamins K and 1,4-NQ affecting different steps of a-syn ﬁbrillization. (A) Thio-T ﬂuorescence at the steady state in the system in which the compounds (30 lM) were
added to a-syn monomer at either the initial time or after 3 days of aggregation at 37 C under agitation. (B) Fibrillization of a-syn in seeding conditions. a-syn monomer, in
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Fig. 4. Vesicle leakage induced by a-syn protoﬁbrils. a-syn protoﬁbrils (20 lM in
terms of monomer concentration) formed in the presence of equimolar concentra-
tions of vitamins K or 1,4-NQ (or 1% DMSO) were added to the LUV composed by PG.
The vesicles of PG were loaded with carboxyﬂuorescein and the enhancement of
ﬂuorescence signal due to the ﬂuorescent dye release was monitored. A leakage of
100% was taken as that produced by addition of 0.1% Triton X-100.
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(Caughey and Lansbury, 2003). a-syn protoﬁbrils can bind to syn-
thetic vesicles causing transient permeabilization that could trig-
ger off toxic events to the cell (Volles et al., 2001; Lashuel et al.,
2002). This ﬁnding could explain the connection between a-syn
mutations, which slightly accelerate in vitro oligomerization of a-
syn, and PD. The a-syn monomer or mature ﬁbrils do not display
vesicle permeabilization property. Herein, we investigate the effect
of a-syn aggregates, generated in the presence of vitamins K, on
vesicle integrity using LUV composed by PG (acidic vesicles). Ves-
icles composed by PG have been previously used in studies of ves-
icle permeabilizaiton by protoﬁbrillar a-syn (Volles et al., 2001).
The vesicles (approximate diameter of 80 nm) were loaded with
carboxyﬂuorescein and the enhancement of ﬂuorescence signal
due to the ﬂuorescent dye release, which occurs during vesicle
leakage, was monitored. A leakage of 100% was taken as that pro-
duced by addition of 0.1% Triton X-100. a-syn monomer was incu-
bated with vitamins K or DMSO under aggregation conditions and
the aggregates formed at the end of lag phase, i.e. prior the forma-
tion of large ﬁbrils, were added to the extravesicular space. Alpha-
syn aggregates (monomer concentration of 20 lM) incubated for
three days with 1% DMSO produced 100% of leakage whereas those
formed in the presence of 100 lM of phylloquinone, menaquinone
or menadione have a reduced leakage activity (10–40%) (Fig. 4).
Similar results were veriﬁed for aggregates incubated with
1,4-NQ. Either compounds alone or DMSO did not produce ﬂuores-
cence enhancement. Additionally, no effect was observed for a-syn
ﬁbrils in concordance with previous studies. Our data indicate thatthe incubation of a-syn monomer for short period of time leads to
formation of aggregates capable to promote vesicle leakage,
whereas the incubation in the presence of either vitamins K or
1,4-NQ produced, aggregates with a reduced ability to leak vesi-
cles. These data suggest that vitamins K could preclude the forma-
tion of protoﬁbrils involved in vesicle permeabilization.
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K
To shed light on the mechanism involved in the interaction be-
tween vitamins K and a-syn, we carried out 1H-15N HSQC NMR
analysis of 15N-a-syn in the presence of the compounds. With this
approach, we sought to determine the residues that could be tak-
ing part on this interaction through the 15N and 1H chemical shift
perturbations. Fig. 5A shows the HSQC spectrum of a-syn (blue)
superposed with the spectrum of a-syn plus phylloquinone (red).
This proﬁle was quite similar for a-syn in the presence of mena-
quinone, menadione or 1,4-NQ (data not shown). From the com-
parison of the spectra, we have determined the variation of
chemical shifts (Dd 1H,15N) of each a-syn residue caused by the
presence of the compounds (Fig. 5B–E). The greatest values for
Dd (1H,15N) are presumably associated to a-syn residues involved
to the interaction with the compounds. The changes in the His50
were neglected since this residue is very sensitive to slight pH
changes and then its involvement in the interaction could be over-
estimated. Analyzing the similarities among vitamins K and 1,4-
NQ, we can observe that all these compounds have perturbed the
Gly31/Lys32 residues suggesting that these residues might play
an important role on the interaction with 1,4-NQ scaffold. The
Val3 was slightly perturbed by menaquinone, menadione and
1,4-NQ but not by phylloquinone,A
B
D
F
Fig. 5. Binding of a-syn monomer to vitamins K or 1,4-NQ. (A) 1H-15N HSQC NMR spe
Phylloquinone (red). The panels (B) to (E) show the changes in chemical shifts of a-syn i
signiﬁcant chemical shift changes were deﬁned based on values above the average of al
(residues 1–61), containing four imperfect KTKEGV hydrophobic, is suggested to be inv
perturbation in the residues located in the more hydrophobic portion (NAC) (residues 61–
the references to colour in this ﬁgure legend, the reader is referred to the web version oThree distinctive domains can be noted in the a-syn sequence
(Fig. 5F). The ﬁrst one is the highly conversed N-terminal domain
(residues 1–61) involved in the binding to phospholipid vesicles
(Eliezer et al., 2001). This domain contains four imperfect KTKEGV
repeats and shows an amphipathic character with propensity to
acquire a-helical structure (Chandra et al., 2003). The second do-
main is a variable internal hydrophobic NAC (non-amyloid compo-
nent) domain (residues 61–95), which is essential for the protein
aggregation. The third one is the C-terminal acid tail (residues
95–140), which is composed primary by negatively charged aspar-
tate and glutamate residues. The interacting environment of the N-
terminal permits to a-syn exhibit different conformations from
random coil to a-helices or b-conformation. According to the
chemical shift changes observed in the HSQC spectrum of a-syn
in the presence of vitamins K, the second repeat domain in the
N-terminal (containing the Lys32) is involved in the binding to
these molecules. This interaction is likely mediated by the 1,4-
NQ scaffold since the chemical shift changes at Gly31/Lys32 are
not greatly affect by the substituent in the 3-position of the ring.
Analyzing the hydrophobic character of the a-syn residues
(Fig. 5F) we can verify that either vitamins K or 1,4-NQ did not pro-
duce any perturbation in the residues located in the most hydro-
phobic portion (NAC) of the protein. Furthermore, the residues
Gly31/Lys32 belong to a low hydrophobic region (indicated by an
arrow in Fig. 5F) reinforcing the idea of the effect observed forC
E
ctrum of 100 lM a-syn alone (blue) or in presence of equimolar concentration of
n presence of phylloquinone, menaquinone, menadione and 1,4-NQ, respectively. A
l chemical shifts. (F) Hydrophobicity of the a-syn domains. The N-terminal domain
olved in the binding to vitamins K or 1,4-NQ. These molecules do not produce any
95). The arrow indicates the location of Gly31/Lys32 residues. (For interpretation of
f this article.)
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interaction. The N-terminal a-syn region contains the three mis-
sense mutations linked to familial PD (A30P, E46K, and A53T),
which have been associated to conformational changes of the
protein, notably in secondary structure (A30P or A53T) or a net
charge (E46K). Therefore, the binding of vitamins K to this domain
might also alter the structure propensity of a-syn.
The repeat domain in a-syn plays a critical role in both kinetic
of ﬁbrillation and in the morphology of the ﬁbrils formed (Harada
et al., 2009). For instance, the mutation E46K occurs in the repeat
sequences and accelerates the ﬁbrillization in vitro and in cultured
cells (Greenbaum et al., 2005; Pandey et al., 2006). In addition,
the E35K, E61K and E83K a-syn mutations perturb the cross
b-structures in N-terminal region, resulting in the formation of
short ﬁbrils rather than the mature ﬁbrils (Harada et al., 2009).
In our studies, vitamins K as well as 1,4-NQ are suggested to
interact with the N-terminal a-syn and promote the formation of
short and sheared ﬁbrils similarly to reported for some mutations
in the repeat sequences.
In contrast with our results, the catechol derivatives entaca-
pone, tolcapone and quercetin, which inhibit a-syn ﬁbrillization,
do not bind to a-syn monomer as veriﬁed by NMR spectroscopy
even in a molar radios up to 1:10 a-syn:compound (Di Giovanni
et al., 2010). These compounds do not produce any signiﬁcant
chemical shift alterations in the HSQC spectrum of a-synmonomer,
with exception of very minor chemical shift changes for His50 and
some N-terminal residues. These chemical shift changes in His50
and the two to three N-terminal residues are also observed for
vitamins K and were ascribed to slight changes in pH. Similar
results were reported for a-syn in the presence of selegiline (Braga
et al., 2011). Selegiline did not produce any perturbation in the
HSQC spectrum of a-syn monomer (Braga et al., 2011), suggesting
the mechanism lying behind the anti-ﬁbrillogenic activity of these
molecules is different than that observed for vitamins K.3.5. Binding of a-syn to quinones and polyphenols
The molecular basis of vitamins K acting as anti-ﬁbrillogenic
agent might be clariﬁed comparing these molecules to others qui-
nones. Imino bonds might be formed by nucleophilic attack of ami-
no groups of a-syn residues on quinones. Similar mechanisms
might lie behind the anti-ﬁbrillogenic activity of polyphenols.
Polyphenols can be spontaneously oxidized in the presence of oxy-
gen into quinones. Epigallocatechin gallate, a polyphenol from
green tea, inhibits a-syn ﬁbrillization with a EC50 value of 20 lM,
which is in the same range of those observed for vitamins K or
1,4-NQ (Li et al., 2005).
It has been reported that the reaction of a-syn with quinones
presumably involves the side chains of Tyr, Lys or Met residues
(Li et al., 2005). Studies with a-syn mutants suggested that Tyr res-
idues do not participate of the interaction with quinones (Norris
et al., 2005), whereas Met residues are more prone to be oxidized
by reactive oxygen species generated during the oxidation of the
polyphenols, catechols or hydroquinones into quinones that might
occurs during the incubation process (Li et al., 2005). On the other
hand, chemical shift changes in 1H-15N HSQC NMR spectrum of
a-syn in the presence of quinone or hydroquinones provide
evidences for the reaction between quinone and e-amino groups
of Lys residues or the a-amino group in the protein N-terminus.
Interestingly, the nonamyloidogenic variant of a-syn (a-syn1–60)
is also able to react with quinone, suggesting that Lys at N-terminal
domain might be involved in this interaction (Li et al., 2005). The
Lys residues are majority found in the N-terminal region of a-syn
and the KTKEGV repeat sequences might represent probable sites
for the interaction with quinones. The Lys32 is found in one ofthese KTKEGV repeats and it is candidate to interact with 1,4-NQ
scaffold of vitamins K.
The ﬂavonoid baicalein (Fig. 1) exhibits anti-ﬁbrilligenic action
on a-syn that promotes the formation of oligomers rather than
ﬁbrils (Zhu et al., 2004). Although the inhibition of a-syn
ﬁbrillization by baicalein occurs in the micromolar range, similarly
to vitamins K, the product of baicalein action on a-syn is soluble
oligomers, whereas vitamins K action results in short ﬁbrils and
amorphous aggregates. Like vitamins K, baicalein affects a-syn
nucleation but not the ﬁbril elongation, and is capable to disaggre-
gate mature ﬁbrils similarly to menadione and 1,4-NQ. Baicalein
covalently bind to the protein molecule through a binding between
the quinone moiety and the Lys side chain resulting in a Schiff
base. Taken together, these data reinforce the idea of vitamins K
interact with a-syn through the N-terminal domain and, more
important, Lys residues participate in the binding process.
The naturally occurring pyrroloquinoline quinone (PQQ) (Fig. 1)
is capable to inhibit the ﬁbrillization of a-syn, even though it is a
less effective anti-ﬁbrillogenic agent than baicalein (Kobayashi
et al., 2006). Regarding its broad spectrum of activities and positive
effect on cellular growth, PQQ has been suggested as an essential
nutrient and even considered as a new form of vitamin B (Killgore
et al., 1989; Kasahara and Kato, 2003). Besides a-syn, PQQ also pre-
vents the in vitro ﬁbrillization of both amyloid-b (1–42) and mouse
prion protein (Kim et al., 2010a). Additionally, PQQ is able to inhi-
bit the ﬁbrillization of C-terminal truncated a-syn119 and 133
resulting in the formation of species with reduced cytotoxicity
(Kim et al., 2010b). Interestingly, C-terminal truncation of a-syn
accelerates the ﬁbrillization and, more importantly, these forms
have been found in both the normal and the pathogenic brain
(Muntané et al., 2012).
In contrast with vitamin A, the anti-ﬁbrillogenic activity of PQQ
on a-syn seems not to be due to nonspeciﬁc hydrophobic
interactions. It has been demonstrated that PQQ interact with
a-syn via formation of Schiff base with Lys residues, resulting in a
PQQ-conjugated a-syn (Kobayashi et al., 2006, 2009). In this
context, the inhibitory property of PQQ is directly associated to
number and location of Lys that are modiﬁed, notably those located
in N-terminus region (Kim et al., 2010a). The formation of Schiff
base with Lys residues was also proposed to occur between a-syn
and other quinones such as baicalein, dopaminechrome and
vitamins K. It must be kept in mind that 10 from 15 Lys residues
are located in the imperfect repeat sequences in N-terminal a-syn.
Additional valuable data on the anti-ﬁbrillogenic action of qui-
nones might be gained from the investigation of the effect of dopa-
mine quinones such as dopaminechrome (DAQ), on a-syn
aggregation. Oxidative stress, dopamine metabolism and a-syn
misfolding are tightly interconnected events in PD neuropathogen-
esis. Lansbury and co-workers demonstrated for the ﬁrst time that
DAQ and others catecholamines are capable of inhibiting a-syn
ﬁbrillization by formation of a covalent adduct (Conway et al.,
2001). DAQ is also capable to promote degradation of pre-existing
ﬁbrils and stabilize cytotoxic protoﬁbrils of a-syn variants, notably
from A30P mutant (Li et al., 2004; Follmer et al., 2007). Structur-
ally, DAQ displays a 1,2-benzoquinone scaffold in contrast with
1,4-NQ of vitamins K (Fig. 1).
The molecular basis of the interaction between DAQ and a-syn
has been widely investigated but the results are often contradic-
tory (To review see: Leong et al., 2009a). While some investigations
have indicated that the generation of toxic protoﬁbrils occurs
through the formation of covalent adducts between of a-syn and
DAQ (Conway et al., 2001; Li et al., 2005; Cappai et al., 2005), a
number of other studies suggest for a non-covalent nature of this
interaction (Norris et al., 2005; Bisaglia et al., 2010). Apparently,
both mechanisms seem to coexist: while a small fraction of a-
syn forms a covalent adduct with DAQ, the majority of the protein
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covalent adducts hypothesis, DAQ was covalently incorporated
into a-synuclein by formation of a Schiff base by nucleophilic at-
tack of Lys on quinone (Li et al., 2005). A covalent bond between
quinone and Lys is also suggested to occur in the interaction of
baicalein with a-syn (Zhu et al., 2004).
On the other hand, Lee and co-workers have shown that DAQ
inhibits a-syn ﬁbrillization by inducing structural changes in
the protein, which is mediated by interaction of DAQ with
the 125YEMPS129 motif of the protein and, most importantly, this
process is reversible (Norris et al., 2005). Interestingly, Follmer
et al. (2007) have demonstrated that a-syn protoﬁbrils formed in
the presence of dopamine are capable to evolving to ﬁbrils when
incubated for a long period of time. Fibrillar structures are also
present in a-syn incubated with vitamins K or 1,4-NQ, beside
amorphous aggregates.
The conﬂicting data about the effect of DAQ on a-syn ﬁbrilliza-
tion might be ascribed to the fact of the experiments were usually
performed by incubating a-syn with dopamine instead of its oxi-
dized form DAQ. Dopamine in aqueous solution is readily oxidized
to DAQ, generating ROS, which in turn might promote the oxida-
tion of certain residues, primarily Met residues (Leong et al.,
2009b). Furthermore, although DAQ may be a stable oxidation
product, it is still capable of undergoing oxidation with time in
route to forming melanin. Thus a-syn oligomerization mediated
by dopamine will be greatly dependent on the oxidation state of
dopamine (Pham et al., 2009). Therefore, misleading conclusions
might arise from the wide range of products generated from dopa-
mine oxidation (dopamine ortho-quinone, dopaminechrome, leu-
codopaminechrome and until melanin) when dopamine is
incubated in the presence of a-syn.
3.6. Potential targets for 1,4-NQ and Vitamins K in the brain
Recent evidences have indicated that vitamins K play an impor-
tant role in the brain (Carrié et al., 2004), including sphingolipid
synthesis and activation of the protein Gas6, this latter involved
in protection against apoptosis and cell proliferation (Ferland
et al., 1992). Low levels of vitamin K have been correlated with
the apolipoprotein Ee4 allele, a risk factor associated with AD
(Allison, 2001). Interestingly, it was demonstrated that Gas6 can
rescue cortical neurons from amyloid-b induced apoptosis besides
a protective role against oxidative damage in developing neurons
(Yagami et al., 2002). Additionally, it has been reported that
patients with early stage AD consume less vitamin K than healthy
subjects (Presse et al., 2008). AD is the condition most commonly
associated with secondary a-syn aggregation (Lippa et al., 2005)
and one-half of the patients with familiar forms of AD have numer-
ous ﬁbrillar a-syn aggregates in the form of Lewy bodies in their
amygdale (Lippa et al., 1998), making a-syn an important target
in the development of therapies not only for PD but also for AD.
The action of vitamins K on a-syn ﬁbrillization seems to be
associated to 1,4-NQ scaffold since 1,4-NQ itself exhibits anti-
ﬁbrillogenic and ﬁbrils dissolving activities, reinforcing the idea
of these and other structurally related 1,4-NQs are lead compounds
for the development of new therapies targeting a-syn aggregation.
Interestingly, our previous studies have suggested that 1,4-NQ is a
potential scaffold for designing new reversible MAO inhibitors. In
case of menadione, it acts as a competitive and reversible inhibitor
of human MAO with 60-fold selectivity for MAO-B (Ki = 0.4 lM) in
relation to MAO-A (Ki = 26 lM), which makes it as selective as
rasagiline (Coelho-Cerqueira et al., 2011). Since MAO catalyzes
the oxidative deamination of biogenic and exogenous amines and
its inhibitors have been used in several neurological conditions
including affective disorders, stroke, neurodegenerative diseases
and aging (Youdim and Bakhle, 2006), 1,4-NQ might represent amultitarget pharmacophore acting on both MAO inhibition and
a-syn ﬁbrillization.4. Conclusions
Although several molecules have been described to inhibit
a-syn ﬁbrillization, many of them behave as promiscuous anti-
ﬁbrillogenic agents, interacting with a-syn through non-speciﬁc
hydrophobic interactions. In contrast with other lipophilic vita-
mins, we demonstrated that the interaction of vitamins K with
a-syn is mediated by speciﬁc residues located at N-terminus
portion of the protein, notably Lys32, leading to the formation of
short ﬁbrils and amorphous aggregates rather than oligomers.
The highly hydrophobic region of the protein involved in the aggre-
gation process (NAC domain) does not participate of this interac-
tion. Taken together, our data pointed out that 1,4-NQ, found in
all forms of vitamins K and many other bioactive molecules, might
represent a potential scaffold for designing drugs targeting a-syn
ﬁbrillization, even though the in vivo effect of these compounds
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